New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04977453
First seen Oct 31, 2025 · Last updated Jun 14, 2026 · Updated 28 times
Summary
This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with certain cancers like lung, kidney, or cervical cancer are being enrolled. This is an early-phase trial, so the main focus is safety and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact
-
Carolina Biooncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact
-
Chungnam National University Hospital
RECRUITINGDaejeon, Daejeon, 65015, South Korea
Contact
-
Ewha Womans University Mokdong Hospital
RECRUITINGSeoul, Yangcheon-gu, 07985, South Korea
Contact
-
Korea University Anam Hospital
RECRUITINGSeoul, Seongbuk-gu, 02841, South Korea
Contact
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam, 06351, South Korea
Contact
-
Seoul National University Bundang Hospital
RECRUITINGSeoul, Bundang-gu, 13620, South Korea
Contact
-
The Catholic University of Korea Seoul ST.MARY'S Hospital
RECRUITINGSeoul, Banpo-daero, 06591, South Korea
Contact
-
The Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, Kyeonggi-do, 16247, South Korea
Contact
-
Tisch Cancer Institute (TCI), Icahn School of Medicine
RECRUITINGNew York, New York, 10029-5674, United States
Contact
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.